Follow

Submissions from 2025

Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology, Minesh Mehta

A New Relevant Integrated Radiologic and Surgical Classification Scheme for Giant Cell Tumors of Bones, Juan Pretell

A nomogram to predict development of brain metastasis in non-small cell lung cancer patients: a retrospective analysis using routinely available medical records, Manmeet Ahluwalia

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC), Adeel Kaiser

A pilot survey into the landscape of neuro-oncology care in the community, Rupesh Kotecha and Yazmin Odia

A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy, Manmeet Ahluwalia

Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases, Sreenija Yarlagadda, Yanjia Zhang, Anshul Saxena, Tugce Kutuk, Ranjini Tolakanahalli, Haley Appel, Roberto Herrera, Matthew Hall, Robert Press, D Jay Wieczorek, Cecilia Lee, Tatiana Bejarano, Michael McDermott, Alonso Gutierrez, Minesh Mehta, and Rupesh Kotecha

A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck, Alessandro Villa

Author Correction: Sex disparities in outcomes among hospitalizations for heart failure, Yanjia Zhang, Muni Rubens, Anshul Saxena, Venkataraghavan Ramamoorthy, Sandra Chaparro, and Javier Jimenez

Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial), Rohan Garje

Back in the RACE: (Re) Defining the Role of Radiation Therapy in Liver and Gallbladder Cancers, Michael Chuong

Beyond Randomized Controlled Trials: Embracing Pragmatism for Evidence-Based Online Adaptive Radiation Therapy, Michael Chuong

PDF

Blue Ribbon Committee I Review: Findings and Impact, Michael Zinner

Blue Ribbon Committee I Review: Findings and Impact, Michael Zinner

Characterization of terminated and withdrawn clinical trials for the treatment and prevention of oral mucositis, Alessandro Villa

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review, Marco Ruiz Andia

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer, Reshma Mahtani

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer, Reshma Mahtani

Clinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group Registry, Omer Gal, Rupesh Kotecha, and Robert Press

Clinical outcomes of modified partial cystectomy in muscle-invasive bladder cancer: balancing tumor control and quality of life, Arjun Pon Avudaiappan

Closed Expander Salvage With Dual-port Tissue Expander in Implant-based Breast Reconstruction for High Body Mass Index and Ptotic Patients, Aneeq Chaudhry, Rita Loureiro, Charo Thomas, Harry Salinas, Matthew Treiser, and Miguel Medina

PDF

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review, Alessandro Villa

Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study, Deerush Sakthivel, Pushan Prabhakar, Rohan Garje, and Murugesan Manoharan

Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry, Nadia Bambace

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis, Reshma Mahtani